Abstract
Loss-of-function variants in CREBBP or EP300 result in Rubinstein–Taybi syndrome (RSTS). The previously reported cluster of variants in the last part of exon 30 and the beginning of exon 31 of CREBBP, overlapping with the ZNF2 (zinc finger, ZZ-type; residues 1701 to 1744) and ZNF3 (zinc finger, TAZ-type; residues 1764 to 1853) domains, is associated with atypical RSTS. The main features include developmental delay, short stature, microcephaly, distinctive facial features, autistic behavior, feeding difficulties, recurrent upper airway infections, and hearing impairment. Here, we report a 2-year-7-month-old Chinese girl presenting mild cognitive impairments, developmental delay, short stature, recurrent upper airway infections, and facial dysmorphism that resembled the phenotypes of previously reported atypical RSTS patients. The characteristic facial and limb dysmorphism for RSTS was absent in our patient. In addition, our patient exhibited novel phenotypes including attention deficit hyperactivity disorder (ADHD), sleep problem, and abnormal walking posture. Whole-exome sequencing (WES) identified a novel de novo in-frame deletion variant in the beginning of exon 30 of CREBBP (NM_004380:c.4897_4899delTTC, p.Phe1633del) in the HAT domain where no pathogenic variants have been previously reported to be responsible for atypical RSTS. Our case allows us to more accurately define the borders of the CREBBP coding sequence resulting in atypical RSTS, which are extended to the beginning of exon 30 (residue 1633) at the 5′ end of CREBBP in the HAT domain, and reveals novel phenotypes observed in our atypical Chinese RSTS patient.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Angius A, Uva P, Oppo M, Persico I, Onano S, Olla S, Pes V, Perria C, Cuccuru G, Atzeni R, Serra G, Cucca F, Sotgiu S, Hennekam RC, Crisponi L (2019) Confirmation of a new phenotype in an individual with a variant in the last part of exon 30 of CREBBP. Am J Med Genet A 179(4):634–638. https://doi.org/10.1002/ajmg.a.61052
Banka S, Sayer R, Breen C, Barton S, Pavaine J, Sheppard SE, Bedoukian E, Skraban C, Cuddapah VA, Clayton-Smith J (2019) Genotype-phenotype specificity in Menke-Hennekam syndrome caused by missense variants in exon 30 or 31 of CREBBP. Am J Med Genet A 179(6):1058–1062. https://doi.org/10.1002/ajmg.a.61131
Bartsch O, Schmidt S, Richter M, Morlot S, Seemanová E, Wiebe G, Rasi S (2005) DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS. Hum Genet 117(5):485–493. https://doi.org/10.1007/s00439-005-1331-y
Carli D, Fairplay T, Ferrari P, Sartini S, Lando M, Garagnani L, Gennaro GLD, Pancrazio LD, Bianconi G, Elmakky A, Bernasconi S, Landi A, Percesepe A (2013) Genetic basis of congenital upper limb anomalies: analysis of 487 cases of a specialized clinic. Birth Defects Res A Clin Mol Teratol 97(12):798–805. https://doi.org/10.1002/bdra.23212
De Guzman RN, Liu HY, Martinez-Yamout M, Dyson HJ, Wright PE (2000) Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J MolBiol 303(2):243–253. https://doi.org/10.1006/jmbi.2000.4141
Hennekam RC (2006) Rubinstein–Taybi syndrome. Eur J Hum Genet 14(9):981–985. https://doi.org/10.1038/sj.ejhg.5201594
Lopez-Atalaya JP, Gervasini C, Mottadelli F, Spena S, Piccione M, Scarano G, Selicorni A, Barco A, Larizza L (2012) Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome. J Med Genet 49(1):66–74. https://doi.org/10.1136/jmedgenet-2011-100354
Menke LA, van Belzen MJ, Alders M, Cristofoli F, The DDD Study, Ehmke N, Fergelot P, Foster A, Gerkes EH, Hoffer MJV, Horn D, Kant SG, Lacombe D, Leon E, Maas SM, Melis D, Muto V, Park SM, Peeters H, Peters DJM, Pfundt R, van Ravenswaaij-Arts CMA, Tartaglia M, Hennekam RCM (2016) CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype. Am J Med Genet A 170(10):2681–2693. https://doi.org/10.1002/ajmg.a.37800
Menke LA, DDD study, Gardeitchik T et al (2018) Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein–Taybi syndrome. Am J Med Genet A 176(4):862–876. https://doi.org/10.1002/ajmg.a.38626
Murata T, Kurokawa R, Krones,A, Tatsumi K, Ishii M, Taki T, Masuno M, Ohashi H, Yanagisawa M, Rosenfeld MG, Glass CK, Hayashi Y (2001) Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet 10(10):1071–1076. https://doi.org/10.1093/hmg/10.10.1071
Petrij F, Giles RH, Dauwerse HG et al (1995) Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376(6538):348–351. https://doi.org/10.1038/376348a0
Ponting CP, Blake DJ, Davies KE, Kendrick-Jones J, Winder SJ (1996) ZZ and TAZ: new putative zinc fingers in dystrophin and other proteins. Trends BiochemSci 21(1):11–13
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30
Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen JT, van Ommen GJB, Breuning MH, Hennekam RC, Peters DJM (2005) Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet 76(4):572–580. https://doi.org/10.1086/429130
Schorry EK, Keddache M, Lanphear N, Rubinstein JH, Srodulski S, Fletcher D, Blough-Pfau RI, Grabowski GA (2008) Genotype-phenotype correlations in Rubinstein-Taybi syndrome. Am J Med Genet A 146A(19):2512–2519. https://doi.org/10.1002/ajmg.a.32424
Sharma N, Mali AM, Bapat SA (2010) Spectrum of CREBBP mutations in Indian patients with Rubinstein-Taybi syndrome. J Biosci 35(2):187–202. https://doi.org/10.1007/s12038-010-0023-5
Spena S, Milani D, Rusconi D, Negri G, Colapietro P, Elcioglu N, Bedeschi F, Pilotta A, Spaccini L, Ficcadenti A, Magnani C, Scarano G, Selicorni A, Larizza L, Gervasini C (2015) Insights into genotype-phenotype correlations from CREBBP point mutation screening in a cohort of 46 Rubinstein-Taybi syndrome patients. Clin Genet 88(5):431–440. https://doi.org/10.1111/cge.12537
Tajir M, Fergelot P, Lancelot G, Elalaoui SC, Arveiler B, Lacombe D, Sefiani A (2013) Germline mosaicism in Rubinstein-Taybi syndrome. Gene 518(2):476–478. https://doi.org/10.1016/j.gene.2012.12.105
van Belzen M, Bartsch O, Lacombe D, Peters DJ, Hennekam RC (2011) Rubinstein-Taybi syndrome (CREBBP, EP300). Eur J Hum Genet 19(1):118–120. https://doi.org/10.1038/ejhg.2010.124
Wincent J, Luthman A, van Belzen M, van der Lans C, Albert J, Nordgren A, Anderlid BM (2015) CREBBP and EP300 mutational spectrum and clinical presentations in a cohort of Swedish patients with Rubinstein-Taybi syndrome. Mol Genet Genomic Med 4(1):39–45. https://doi.org/10.1002/mgg3.177
Acknowledgments
We would like to express our sincere gratitude to our patient and her family for their cooperation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at Dongguan Maternal and Child Health Care Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Written informed consent was obtained from the family.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
ESM 1
(DOCX 20 kb)
Rights and permissions
About this article
Cite this article
Wang, Q., Xu, W., Liu, Y. et al. A Novel CREBBP in-Frame Deletion Variant in a Chinese Girl with Atypical Rubinstein–Taybi Syndrome Phenotypes. J Mol Neurosci 71, 607–612 (2021). https://doi.org/10.1007/s12031-020-01681-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-020-01681-x